Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial
W. Eberhardt et al., Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial, BR J CANC, 81(7), 1999, pp. 1206-1212
Following mediastinoscopy, a prognostically orientated multimodality approa
ch was chosen in selected small-cell lung cancer (SCLC) patients with hyper
fractionated accelerated chemoradiotherapy (Hf-RTx) and definitive surgery
(S). Stage IB/IIA patients had four cycles of cisplatin/etoposide (PE) and
surgery. Stage IIB/IIIA patients had three cycles PE followed by one cycle
concurrent chemoradiation including Hf-RTx and surgery. Most stage IIIB pat
ients were not planned for surgery and had CTx followed by sequential RTx o
r one cycle concurrent CTx/RTx. Of 46 consecutive patients (stage IB six, I
IA two, IIB/IIIA 22, IIIB 16) 43 (94%) showed an objective response. Twenty
-three of patients (72%) planned for inclusion of S were completely resecte
d (RO) (IB 6/6, IIA 2/2, IIB/IIIA 13/22, IIIB 2/2). Overall toxicity was ac
ceptable - one patient died of septicaemia, no perioperative deaths occurre
d. Median follow-up of patients alive (n = 21) is 52 months (30+ - 75+). Me
dian survival and 5-year survival rate of all patients are 36 months and 46
%, in RO patients 68 months and 63% (RO-IIB/IIIA/IIIB: not yet reached and
67%), This multimodality treatment including surgery proved highly effectiv
e with 100% local control and remarkable long-term survival after complete
resection, even in locally advanced SCLC stages IIB/IIIA patients, (C) 1999
Cancer Research Campaign.